ESAS and FACT-B in eribulin-treated metastatic breast cancer patients: a multicenter, prospective and observational study

被引：3
|
作者：
Moscetti, Luca [1 ,7 ]
Mentuccia, Lucia [2 ]
Vici, Patrizia [3 ]
Quadrini, Silvia [2 ]
Sperduti, Isabella [4 ]
Pizzuti, Laura [3 ]
Fabbri, Maria Agnese [1 ]
Vaccaro, Angela [2 ]
Sacca, Marcello Maugeri [3 ,6 ]
Barba, Maddalena [3 ,6 ]
Sergi, Domenico [3 ]
Zampa, Germano [5 ]
Gamucci, Teresa [2 ]
机构：
[1] Belcolle Hosp, AUSL Viterbo, Div Med Oncol, Viterbo, Italy
[2] ASL Frosinone, Med Oncol Unit, Frosinone, Italy
[3] Regina Elena Inst Canc Res, Div Med Oncol B, Rome, Italy
[4] Regina Elena Inst Canc Res, Biostat, Rome, Italy
[5] Nuovo Regina Margherita Hosp, Med Oncol Unit, Rome, Italy
[6] Regina Elena Inst Canc Res, Sci Direct, Rome, Italy
[7] Azienda Osped Univ Policlin Modena, Dept Oncol & Hematol, Modena, Italy
来源：
FUTURE ONCOLOGY | 2017年 / 13卷 / 17期
关键词：
Edmonton symptoms assessment scale; eribulin mesylate; metastatic breast cancer; quality of life; QUALITY-OF-LIFE; CAPECITABINE; MESYLATE; SCALE;
D O I：
10.2217/fon-2017-0062
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Aim: Quality of life (QoL) is a critical issue for women with metastatic breast cancer (MBC). Eribulin mesylate represents a novel and active drug for pretreated MBC. Regretfully, few data exploring health-related (HR) QoL are available in unselected populations. Patients & methods: A multicenter prospective observational study was conducted in 50 MBC patients treated with eribulin mesylate, in order to evaluate HRQoL and patients' well-being by using the Edmonton symptoms assessment scale (ESAS) and Functional Assessment of Cancer Therapy-Breast questionnaires. Results: A significant ESAS score improvement was observed with a 10% median decrease. No differences were revealed for the QoL scores. Conclusion: The analysis of ESAS and Functional Assessment of Cancer Therapy scores showed that eribulin mesylate contributes to preserve QoL in MBC patients.
引用
收藏
页码：1517 / 1525
页数：9
相关论文
共 50 条
  • [31] Management of elderly breast cancer patients in Spain: A national observational, prospective, multicenter study
    Clopes, A
    Paladio, N
    Cajaraville, G
    Carreras, MJ
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 755S - 755S
  • [32] Measurement properties of the English and Chinese versions of the Functional Assessment of Cancer Therapy—Breast (FACT-B) in Asian breast cancer patients
    Raymond Ng
    Chun Fan Lee
    Nan Soon Wong
    Nan Luo
    Yoon Sim Yap
    Soo Kien Lo
    Whay Kuang Chia
    Alethea Yee
    Lalit Krishna
    Cynthia Goh
    Yin Bun Cheung
    [J]. Breast Cancer Research and Treatment, 2012, 131 : 619 - 625
  • [33] Outcome in Patients with Metastatic Breast Cancer Treated with Eribulin: A Real-world Cohort
    Rush, H.
    Khan, M.
    Li, S.
    Agorastos, A.
    Kristeleit, H.
    [J]. CLINICAL ONCOLOGY, 2018, 30 (06) : E46 - E46
  • [34] A prospective multicenter observational study of bevacizumab for the treatment of metastatic colorectal cancer in Chinese patients (Obtain study).
    Wang, Fenghua
    Dai, Guanghai
    Deng, Yanhong
    Tang, Yong
    Wang, Wei
    Niu, Zuoxing
    Bi, Feng
    Zhu, Liangjun
    Guo, Zengqing
    Yan, Jin
    Hu, Bing
    Tao, Min
    Yang, Shujun
    Zhang, Suzhan
    Wen, Lu
    Xu, Ruihua
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [35] TREATMENT WITH ERIBULIN (HALAVEN) IN HEAVILY PRE-TREATED PATIENTS WITH METASTATIC BREAST CANCER
    Lynge, M.
    Liposits, G. I.
    Linnet, S.
    Langkjer, S. T.
    [J]. BREAST, 2013, 22 : S43 - S43
  • [36] Treatment with eribulin (halaven) in heavily pre-treated patients with metastatic breast cancer
    Rasmussen, Maja Lynge
    Liposits, Gabor
    Yogendram, Subethini
    Jensen, Anders Bonde
    Linnet, Soren
    Langkjer, Sven Tyge
    [J]. ACTA ONCOLOGICA, 2014, 53 (09) : 1275 - +
  • [37] Body Mass Index and Treatment Outcomes in Metastatic Breast Cancer Patients Treated With Eribulin
    Barba, Maddalena
    Pizzuti, Laura
    Sperduti, Isabella
    Natoli, Clara
    Gamucci, Teresa
    Sergi, Domenico
    Di Lauro, Luigi
    Moscetti, Luca
    Izzo, Fiorentino
    Rinaldi, Massimo
    Mentuccia, Lucia
    Vaccaro, Angela
    Iezzi, Laura
    Grassadonia, Antonino
    Michelotti, Andrea
    Landucci, Elisabetta
    Perracchio, Letizia
    Pescarmona, Edoardo
    Di Filippo, Franco
    Giordano, Antonio
    Maugeri-Sacca, Marcello
    Vici, Patrizia
    [J]. JOURNAL OF CELLULAR PHYSIOLOGY, 2016, 231 (05) : 986 - 991
  • [38] Is eribulin treatment prognostic factor in patients with metastatic breast cancer treated with this drug? Retrospective analysis of a multicentre study
    Oruc, Zeynep
    Kaplan, Muhammet Ali
    Geredeli, Caglayan
    Sari, Nilgun Yildirim
    Ozaslan, Ersin
    Aytekin, Aydin
    Elkiran, Emin Tamer
    Koca, Sinan
    Dogan, Mutlu
    Turan, Nedim
    Yuce, Ozlem
    Sevinc, Alper
    Ercelep, Ozlem
    Isikdogan, Abdurrahman
    [J]. JOURNAL OF BUON, 2020, 25 (02): : 641 - 647
  • [39] Italian observational study of Eribulin Mesylate in patients with advanced breast cancer: ESEMPiO study
    Barni, S.
    Fontanella, C.
    Del Mastro, L.
    Livraghi, L.
    Morritti, M.
    Pizzuti, L.
    Michelotti, A.
    Lutrino, E. S.
    Ciccarese, M.
    Musolino, A.
    Quercia, S.
    Garrone, O.
    Pellegrino, A.
    Pistelli, M.
    Martella, F.
    Iezzi, L.
    Mentuccia, L.
    Latorre, A.
    D'Onofrio, L.
    Porcu, L.
    [J]. EUROPEAN JOURNAL OF CANCER, 2015, 51 : S281 - S282
  • [40] Measurement properties of the English and Chinese versions of the Functional Assessment of Cancer Therapy-Breast (FACT-B) in Asian breast cancer patients
    Raymond Ng
    Lee, Chun Fan
    Wong, Nan Soon
    Luo, Nan
    Yap, Yoon Sim
    Lo, Soo Kien
    Chia, Whay Kuang
    Yee, Alethea
    Krishna, Lalit
    Goh, Cynthia
    Cheung, Yin Bun
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2012, 131 (02) : 619 - 625
12345